The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis

Jingjing Zhou, Fang Wang, Sen Li · 2025

Read The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis by Jingjing Zhou, Fang Wang, Sen Li (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12727569.txt.

Description

Zhou, Wang, and Li combine trial results on two new pill drugs for type 2 diabetes and excess weight. Both drugs copy a gut hormone that helps control blood sugar, but unlike older drugs in the class they are taken by mouth. Their 2025 review searched four large databases and kept eight trials with low risk of bias, covering 1,454 people in all.

Both pills lowered blood sugar and body weight by clear margins against the starting point. One drug cut weight by about two kilos on average, while the other cut it by more than six. Both also raised the rate of stomach and gut side effects. The authors call for longer studies to judge lasting benefit and comfort.

Catalog record

CREATORJingjing Zhou, Fang Wang, Sen Li
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12727569

Browse the full library · About the Tower of Babel